NCT05731908已完成1 期
Pharmacokinetics, Safety, and Tolerability of BI 690517 in Subjects With Mild and Moderate Liver Impairment (Child-Pugh Classification A and B) as Compared to Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 2
- 主要终点
- Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
研究概览
简要总结
The main objective of this trial is to assess the effect of mild and moderate hepatic impairment (Child-Pugh classification A and B) on the pharmacokinetics, safety, and tolerability of BI 690517 in comparison with a control group with normal hepatic function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female subjects aged at least 18 years at screening
- •Body mass index of 18.5 to 36.0 kg/m2 (inclusive)
- •Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
- •Women of childbearing potential1 and men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly.
- •Inclusion criteria applying only to participants with impaired hepatic function:
- •Hepatic impairment classified as Child-Pugh A (score 5-6 points) or Child-Pugh B (score 7-9 points)
- •Absence of clinically significant abnormalities, as based on a complete medical history including a full physical examination, vital signs (Blood pressure, Pulse rate), 12-lead Electric Cardiogram, and clinical laboratory tests at both screening and admission to trial site, with the exception of findings that in the opinion of the investigator are consistent with the participant's hepatic impairment.
- •Medication and/or treatment regimens must have been stable (i.e., no dose adjustments) for at least 4 weeks prior to the screening period and should be kept stable until study completion. Fluctuating treatment regimens may be considered for inclusion on a case-by-case basis if the underlying disease is under control in the opinion of the investigator and must be agreed to by both the investigator and the sponsor's medical monitor.
- •Inclusion criteria applying only to healthy participants with normal hepatic function:
- •Healthy subjects according to the following criteria: the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests.
- •Individually matched to participants with hepatic impairment according to sex, age, and weight
排除标准
- •Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
- •Repeated measurements of blood pressure and pulse rate out of range considered clinically significant by the investigator
- •Any laboratory value outside the reference range that the investigator considers to be of clinical relevance, except for laboratory values outside the reference range due to underlying disease
- •Any evidence of a concomitant disease assessed as clinically relevant by the investigator
- •Surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except cholecystectomy, appendectomy or simple hernia repair)
- •Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
- •History of relevant orthostatic hypotension, fainting spells, or blackouts
- •Relevant chronic or acute infections
- •Further exclusion criteria apply
研究组 & 干预措施
BI 690517 mild hepatic impairment (Child-Pugh A)
Experimental
干预措施: BI 690517 (Drug)
BI 690517 normal hepatic function
Experimental
control group
干预措施: BI 690517 (Drug)
BI 690517 moderate hepatic impairment (Child-Pugh B)
Experimental
干预措施: BI 690517 (Drug)
结局指标
主要结局
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
时间窗: Up to 4 days
Maximum measured concentration of the analyte in plasma (Cmax)
时间窗: Up to 4 days
次要结局
- Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)(Up to 4 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver FunctionHealthyHepatic InsufficiencyNCT01111318Boehringer Ingelheim36
终止
1 期
A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver ProblemsHealthyLiver DiseasesNCT06272058Boehringer Ingelheim4
已完成
1 期
Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionHealthyLiver DiseasesNCT02171832Boehringer Ingelheim32
已完成
1 期
Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy SubjectsHepatic InsufficiencyNCT02183376Boehringer Ingelheim33
已完成
1 期
Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control GroupPharmacokinetics of MDV3100Healthy SubjectsKidney DiseasesNCT01901133Astellas Pharma Europe B.V.33